Insider Purchases: Inside the Buy

Tag: long-term investing

Stylized first-aid kit and medical icons sitting on a rising stock chart, symbolizing Johnson & Johnson’s AAA strength and insider buying in JNJ shares.

Director Purchases Shares of Johnson & Johnson

A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?

Read entire article

Tags: blue-chip stocks, Buy-JNJ, buy-or-sell-jnj, director-buying, Dividend Stocks, featured-insiders, funanc1al edge, funanc1al humor, Funanc1al investing, FUNstock Index, Healthcare Stocks, Insider Purchases, JNJ, Johnson & Johnson, Long-Term Investing, MedTech, Pharma & Biotech, risks-buying-jnj, Value Investing, why-buy-jnj
Blackstone investor snapshot: Breyer’s insider buy, strong AUM, dry powder, and growth pillars in PE, real estate, credit, infrastructure

Investor & Insider James Breyer Just Bought Blackstone (BX). Should You Sip the Alt-Assets Kool-Aid—or Sit It Out?

Blackstone remains the alt-assets apex predator: $1.24T AUM, rising perpetual capital, and a fresh insider buy from director James Breyer. We unpack fundraising momentum, distributable earnings, variable dividends, key risks (rates, exits), and why dips may be gifts for long-term investors.

 

Read entire article

Tags: alternative assets, AUM, Blackstone, Buy or sell blackstone stock, BX stock, Director Insider Buying, distributable earnings, Dividends, Dividends & Buybacks, DividendStocks, funanc1al edge, funanc1al humor, FUnanc1al investing, fundraising, infrastructure investing, insider purchases, institutional ownership, James Breyer, long-term investing, private credit, private equity